caption
stringlengths 0
3.92k
| molecule
stringlengths 1
914
| properties
listlengths 1
113
| additional_data
dict |
|---|---|---|---|
The molecule is a optoelectronic.
|
CC1(C)c2cccc(N(C3=CCC(c4ccccc4)CC3)C3C=CC(c4cccc5c4oc4ccccc45)=CC3)c2C2=CC=CCC21
|
[
"optoelectronic"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a inflammatory, energy storage, energy source, membrane stabilizer, fat storage and belongs to the thyroxine treatment class of molecules. The molecule is a nutrient that affects cancer by impacting obesity. It impacts atherosclerosis, pancreatitis, cardiovascular disease, and metabolic syndrome.
|
CCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC
|
[
"inflammatory",
"Energy storage",
"Energy source",
"Membrane stabilizer",
"Thyroxine treatment",
"Fat storage",
"Cancer",
"nutrient",
"Obesity",
"Atherosclerosis",
"Pancreatitis",
"Cardiovascular disease",
"Metabolic syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a angiotensin ii antagonist and belongs to the anti hypertensive class of molecules.
|
CCOc1nc2c(OC(=O)CCOC(=O)OC3CCCCC3)cccc2[nH]1
|
[
"anti hypertensive",
"angiotensin ii antagonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation, a energy storage, and a cholesterol translocation, and it impacts aging. The molecule is a membrane stabilizer, surfactant, emulsifier, nutritional supplement, and smooth. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a food additive, apoptosis, stabilizing mitochondrial structure, energy source that impacts barth syndrome.
|
CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C
|
[
"Proton trap for oxidative phosphorylation",
"Aging",
"Energy storage",
"Cholesterol translocation",
"Smooth",
"Membrane stabilizer",
"surfactant",
"Emulsifier",
"Nutritional supplement",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"food additive",
"Apoptosis",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Energy source"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and tangier disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and aging.
|
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC
|
[
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts tangier disease and aging. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease.
|
CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C
|
[
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a pgd2 receptor antagonist and is allergic disease treatment.
|
CNc1ccc2c(C(C)C)cn(C(C)C)c2n1
|
[
"allergic disease treatment",
"pgd2 receptor antagonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts alzheimer's disease, parkinson's disease, non-alcoholic fatty liver disease, and diabetes mellitus type 2.
|
CCCCCc1oc(CCCCCCCCC(=O)O[C@H](COC(=O)CCCCCC[C@H]2[C@@H](O)CC(=O)[C@@H]2/C=C/[C@@H](O)CCCCC)COP(=O)(O)OCCN)c(C)c1C
|
[
"nutrient",
"Alzheimer's Disease",
"Parkinson's disease",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, and diabetic heart disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts barth syndrome and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC
|
[
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts tangier disease and aging. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC
|
[
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts diabetes mellitus, neurodegenerative disease, and insulin resistance.
|
CC/C=C\C[C@H](O)/C=C/C=C\C/C=C\C=C\[C@H](O)/C=C\CCCC(=O)N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCC
|
[
"Diabetes mellitus",
"Neurodegenerative disease",
"Insulin resistance"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti inflammatory member of the dyslipidemia treatment class.
|
CCOC(=O)CCC(=O)O.CCOC(C)=O
|
[
"dyslipidemia treatment",
"anti inflammatory"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, aging, and diabetic heart disease.
|
CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C
|
[
"Barth syndrome",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Diabetic heart disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a autotaxin inhibitor.
|
NC1CC(C(F)(F)F)CC=C1Br
|
[
"autotaxin inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, a membrane stabilizer, and a energy source, and it impacts tangier disease. The molecule is a emulsifier and a nutritional supplement, which impacts both diabetic heart disease and barth syndrome, and is characterized as smooth. The molecule is a cholesterol translocation, food additive, energy storage, proton trap for oxidative phosphorylation. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging and non-alcoholic fatty liver disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
[
"Tangier disease",
"surfactant",
"Membrane stabilizer",
"Energy source",
"Diabetic heart disease",
"Emulsifier",
"Smooth",
"Barth syndrome",
"Nutritional supplement",
"Cholesterol translocation",
"food additive",
"Energy storage",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy storage, thyroxine treatment, and energy source that has an effect on cancer and impacts both atherosclerosis and pancreatitis. The molecule is a inflammatory that impacts both obesity and metabolic syndrome. The molecule is a membrane stabilizer, a nutrient, and a fat storage, and it impacts cardiovascular disease.
|
CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
|
[
"Atherosclerosis",
"Pancreatitis",
"Cancer",
"Energy storage",
"Thyroxine treatment",
"Energy source",
"Obesity",
"inflammatory",
"Metabolic syndrome",
"Membrane stabilizer",
"Cardiovascular disease",
"nutrient",
"Fat storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C=C\[C@H](O)CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, food additive, emulsifier, surfactant. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and non-alcoholic fatty liver disease. The molecule is a energy storage and smooth, impacting both barth syndrome and tangier disease. The molecule is a energy source, nutritional supplement, membrane stabilizer, stabilizing mitochondrial structure that impacts diabetic heart disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCC
|
[
"Cholesterol translocation",
"food additive",
"Emulsifier",
"surfactant",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Energy storage",
"Tangier disease",
"Smooth",
"Energy source",
"Diabetic heart disease",
"Nutritional supplement",
"Membrane stabilizer",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a energy storage, it impacts tangier disease, and is smooth. The molecule is a proton trap for oxidative phosphorylation, surfactant, energy source, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis and a nutritional supplement, impacting both aging and diabetic heart disease. The molecule is a cholesterol translocation, emulsifier, membrane stabilizer, food additive that impacts barth syndrome.
|
CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C
|
[
"Stabilizing mitochondrial structure",
"Tangier disease",
"Smooth",
"Energy storage",
"Proton trap for oxidative phosphorylation",
"surfactant",
"Non-alcoholic fatty liver disease",
"Energy source",
"Stabilizing cytochrome oxidase",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Nutritional supplement",
"Barth syndrome",
"Cholesterol translocation",
"Emulsifier",
"Membrane stabilizer",
"food additive"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and barth syndrome. The molecule is a apoptosis and a cholesterol translocation that impacts tangier disease, non-alcoholic fatty liver disease, and aging.
|
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)C
|
[
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient, surfactant, membrane stabilizer, floral, and amber. The molecule is a energy source, emulsifier, energy storage, flavoring agent, and woody.
|
CCCCC(CO)C(C)=O
|
[
"floral",
"nutrient",
"amber",
"surfactant",
"Membrane stabilizer",
"Energy source",
"Emulsifier",
"woody",
"Energy storage",
"Flavoring agent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
When heated to decomposition it emits toxic fumes of cadmium. The molecule has Odor of acetic acid.
|
CC(=O)[O-].CC(=O)[O-].[Cd+2]
|
[
"Decomposition_evaluation",
"Odor_evaluation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, tangier disease, and aging.
|
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCC
|
[
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage and thyroxine treatment, and it impacts cardiovascular disease. The molecule is a nutrient that impacts atherosclerosis, pancreatitis, and metabolic syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
|
[
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"Pancreatitis",
"Metabolic syndrome",
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a orexin type 2 receptor agonist.
|
Cl.NC(Cc1cccc(Cl)c1F)C(=O)O
|
[
"orexin type 2 receptor agonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a food additive and a cholesterol translocation, impacting both non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, energy source, stabilizing mitochondrial structure that impacts aging. The molecule is a surfactant, a proton trap for oxidative phosphorylation, and a membrane stabilizer, and it impacts barth syndrome. The molecule is a nutritional supplement, a energy storage, and a emulsifier, it impacts tangier disease and is smooth.
|
CC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C
|
[
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"food additive",
"Cholesterol translocation",
"Apoptosis",
"Aging",
"Stabilizing cytochrome oxidase",
"Energy source",
"Stabilizing mitochondrial structure",
"surfactant",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Membrane stabilizer",
"Nutritional supplement",
"Energy storage",
"Tangier disease",
"Emulsifier",
"Smooth"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy source, energy storage, membrane stabilizer, emulsifier, earthy, and woody. The molecule is a nutrient, a surfactant, herbal, balsam, fir needle, and spicy.
|
CC(=O)c1sc(C)cc1O
|
[
"Energy source",
"Energy storage",
"earthy",
"Membrane stabilizer",
"woody",
"Emulsifier",
"herbal",
"balsam",
"nutrient",
"fir needle",
"surfactant",
"spicy"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage, a inflammatory, and a nutrient that impacts both pancreatitis and atherosclerosis, and is thyroxine treatment. The molecule is a energy storage that affects cancer by impacting cardiovascular disease. The molecule is a membrane stabilizer and a energy source, impacting both obesity and metabolic syndrome.
|
CCC(C)CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCC(C)CC
|
[
"Fat storage",
"inflammatory",
"nutrient",
"Pancreatitis",
"Thyroxine treatment",
"Atherosclerosis",
"Cancer",
"Energy storage",
"Cardiovascular disease",
"Obesity",
"Membrane stabilizer",
"Metabolic syndrome",
"Energy source"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the anti microbial class of molecules.
|
CC(N)CCCc1cc(Cl)c(F)c(-c2cc3cn(-c4ccc(C5NCC(CCN=C(N)N)N5)cc4)c(=O)nc3[nH]2)c1
|
[
"anti microbial"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage that impacts both cardiovascular disease and thyroxine treatment. The molecule is a nutrient that impacts atherosclerosis, pancreatitis, and metabolic syndrome.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC
|
[
"Cardiovascular disease",
"Fat storage",
"Thyroxine treatment",
"Atherosclerosis",
"nutrient",
"Pancreatitis",
"Metabolic syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CC/C=C\CC1OC1C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](N)C(=O)O
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient and thyroxine treatment, and it impacts cardiovascular disease. The molecule is a fat storage that impacts pancreatitis, metabolic syndrome, and atherosclerosis.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCC
|
[
"Cardiovascular disease",
"nutrient",
"Thyroxine treatment",
"Fat storage",
"Pancreatitis",
"Metabolic syndrome",
"Atherosclerosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a apoptosis, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts aging and diabetic heart disease.
|
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCC
|
[
"Tangier disease",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a kinase inhibitor and inflammatory disease treatment, and it impacts diabetes treatment.
|
CC(C)Cc1cc(OC(F)(F)F)ccc1F
|
[
"kinase inhibitor",
"inflammatory disease treatment",
"diabetes treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a ido inhibitor.
|
CCNC(=O)C1CCCCO1
|
[
"ido inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a member of the anti biotic class and affects photoelectric conversion.
|
Cn1[nH]nnc1=S.[K]
|
[
"anti biotic",
"photoelectric conversion"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, aging, barth syndrome, and diabetic heart disease.
|
CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, diabetic heart disease, and aging. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts tangier disease and barth syndrome.
|
CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC
|
[
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Aging",
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a sodium channel inhibitor and is pain treatment.
|
COc1cc(OC(F)(F)F)ccc1Oc1cc(C(F)(F)F)c(C)c(F)c1C(=O)Nc1ccnc(C(N)=O)c1
|
[
"pain treatment",
"sodium channel inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
|
[
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a food additive, a proton trap for oxidative phosphorylation, a cholesterol translocation, and smooth. The molecule is a surfactant, energy storage, stabilizing mitochondrial structure, nutritional supplement that impacts non-alcoholic fatty liver disease. The molecule is a emulsifier that impacts diabetic heart disease, tangier disease, and aging. The molecule is a energy source, membrane stabilizer, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome.
|
CCC(C)CCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCC(C)CC
|
[
"food additive",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Smooth",
"surfactant",
"Energy storage",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Nutritional supplement",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Emulsifier",
"Energy source",
"Membrane stabilizer",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, apoptosis, proton trap for oxidative phosphorylation that impacts aging and diabetic heart disease. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
|
[
"Stabilizing mitochondrial structure",
"Aging",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a membrane stabilizer and a energy source, impacting both non-alcoholic fatty liver disease and tangier disease. The molecule is a energy storage, stabilizing mitochondrial structure, surfactant that impacts aging and barth syndrome. The molecule is a apoptosis, a stabilizing cytochrome oxidase, and a nutritional supplement, and it impacts diabetic heart disease. The molecule is a emulsifier, proton trap for oxidative phosphorylation, cholesterol translocation, food additive, and smooth.
|
CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C
|
[
"Membrane stabilizer",
"Energy source",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Energy storage",
"Aging",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"surfactant",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Nutritional supplement",
"Smooth",
"Emulsifier",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"food additive"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a thyroxine treatment that impacts both pancreatitis and atherosclerosis. The molecule is a fat storage and a nutrient, impacting both metabolic syndrome and cardiovascular disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC
|
[
"Thyroxine treatment",
"Pancreatitis",
"Atherosclerosis",
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts aging, barth syndrome, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC
|
[
"Aging",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Tangier disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, sedative, emulsifier, green, and anti microbial. The molecule is a membrane stabilizer, energy storage, flavoring agent, anti spasmodic, citrus, and woody. The molecule is a energy source, flavor, and fragrance, belonging to the anesthetic class of molecules, and is both bergamot and sweet. The molecule is a motor depressant, anti oxidant, food and nutrition, nutrient, lavender, and fruit.
|
CC1CCC2(OC1)OC1CC3C4CC=C5CC(OC6OC(COC7OC(C)C(O)C(O)C7OC7OC(CO)C(OC8OC(CO)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O)CCC5(C)C4CCC3(C)C1C2C
|
[
"green",
"surfactant",
"sedative",
"Emulsifier",
"anti microbial",
"Membrane stabilizer",
"citrus",
"Energy storage",
"Flavoring agent",
"woody",
"anti spasmodic",
"Energy source",
"flavor",
"bergamot",
"anesthetic",
"sweet",
"fragrance",
"lavender",
"motor depressant",
"anti oxidant",
"Food and nutrition",
"nutrient",
"fruit"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts non-alcoholic fatty liver disease, parkinson's disease, alzheimer's disease, and diabetes mellitus type 2.
|
CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCc1oc(CCCCC)c(C)c1C)COP(=O)(O)OCCN
|
[
"Non-alcoholic fatty liver disease",
"Parkinson's disease",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts aging, non-alcoholic fatty liver disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts tangier disease and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, aging, and barth syndrome.
|
CCC(C)CCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C
|
[
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Aging",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and aging.
|
CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCC
|
[
"Cholesterol translocation",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a renoirritant and nematicide, belonging to the pharmaceutical class of molecules, and is turpentine. The molecule is a energy source, spermicide, herbicide, woody, and earth. The molecule is a anti asthmatic, irritant, anti ulcer, fragrance, and allelopathic. The molecule is a nutrient, which belongs to both the anti oxidant and anti acne classes, and is characterized as being both sweet and pepper. The molecule is a insectifuge and anti allergic agent, belonging to the fungicide class of molecules, and is both musty and anti septic. The molecule is a flavoring agent and flavor, belonging to the anti radicular class of molecules, and is both must and nutmeg. The molecule is a ec 3.1.1.7 (acetylcholinesterase) inhibitor and energy storage, belonging to the bacteriostatic class of molecules, and is both vulnerary and anti spasmodic. The molecule is a membrane stabilizer, surfactant, emulsifier, pesticide, and diuretic.
|
CC1=CCC2(C)C(O)CC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC43C)C2C1C
|
[
"Pharmaceutical",
"renoirritant",
"nematicide",
"turpentine",
"Energy source",
"woody",
"spermicide",
"herbicide",
"earth",
"anti asthmatic",
"irritant",
"allelopathic",
"anti ulcer",
"fragrance",
"anti oxidant",
"nutrient",
"anti acne",
"sweet",
"pepper",
"fungicide",
"insectifuge",
"musty",
"anti allergic agent",
"anti septic",
"anti radicular",
"must",
"Flavoring agent",
"nutmeg",
"flavor",
"vulnerary",
"EC 3.1.1.7 (acetylcholinesterase) inhibitor",
"Energy storage",
"anti spasmodic",
"bacteriostatic",
"Membrane stabilizer",
"surfactant",
"Emulsifier",
"diuretic",
"pesticide"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts diabetic heart disease, aging, and tangier disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
|
[
"Diabetic heart disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is anti viral.
|
CN(C)C1CCN(c2cc(N3CCC(c4ccc(Cl)cc4)CC3)c(F)cc2C=NNC(N)=S)C1
|
[
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a wnt pathway inhibitor.
|
CS(=O)(=O)NCc1cc(F)cc(-c2ccnc3nc(-c4n[nH]c5cnc(C6CCNCC6)cc45)[nH]c23)c1
|
[
"wnt pathway inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC
|
[
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and tangier disease.
|
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCC(C)C
|
[
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient and a environmental contaminant that impacts lethargy, weight loss, and erythema.
|
O=C(CCCCC/C=C/c1ccc2c(c1)OCO2)N1CCCCC1
|
[
"Lethargy",
"Weight loss",
"nutrient",
"environmental contaminant",
"Erythema"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage that impacts both pancreatitis and metabolic syndrome. The molecule is a nutrient that impacts cardiovascular disease, atherosclerosis, and thyroxine treatment.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
|
[
"Pancreatitis",
"Metabolic syndrome",
"Fat storage",
"Cardiovascular disease",
"Atherosclerosis",
"nutrient",
"Thyroxine treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage, inflammatory, energy storage that impacts metabolic syndrome, cancer, and pancreatitis. The molecule is a membrane stabilizer and thyroxine treatment, and it impacts obesity. The molecule is a energy source and a nutrient, impacting both cardiovascular disease and atherosclerosis.
|
CCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC
|
[
"Metabolic syndrome",
"Cancer",
"Fat storage",
"inflammatory",
"Energy storage",
"Pancreatitis",
"Membrane stabilizer",
"Thyroxine treatment",
"Obesity",
"Energy source",
"nutrient",
"Cardiovascular disease",
"Atherosclerosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant and a stabilizing cytochrome oxidase, it impacts non-alcoholic fatty liver disease, and is smooth. The molecule is a energy source, emulsifier, energy storage, proton trap for oxidative phosphorylation that impacts aging. The molecule is a cholesterol translocation, a stabilizing mitochondrial structure, and a apoptosis, and it impacts diabetic heart disease. The molecule is a nutritional supplement, membrane stabilizer, food additive that impacts tangier disease and barth syndrome.
|
CCC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C
|
[
"Non-alcoholic fatty liver disease",
"surfactant",
"Stabilizing cytochrome oxidase",
"Smooth",
"Energy source",
"Emulsifier",
"Aging",
"Energy storage",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Nutritional supplement",
"Tangier disease",
"Membrane stabilizer",
"food additive",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a protease inhibitor.
|
CCC1C(=O)N(C)C(N)=NC1(C)c1cc(-c2cccc(Br)c2)cs1
|
[
"protease inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a inflammatory, membrane stabilizer, fat storage that belongs to the thyroxine treatment class of molecules and impacts both atherosclerosis and pancreatitis. The molecule is a nutrient and energy storage with an effect on cancer. The molecule is a energy source that impacts metabolic syndrome, cardiovascular disease, and obesity.
|
CC(C)CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C
|
[
"inflammatory",
"Membrane stabilizer",
"Thyroxine treatment",
"Atherosclerosis",
"Pancreatitis",
"Fat storage",
"Cancer",
"nutrient",
"Energy storage",
"Metabolic syndrome",
"Energy source",
"Cardiovascular disease",
"Obesity"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC
|
[
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Diabetic heart disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti malarial.
|
C=C(c1ccc(Cl)cc1)C1COC2(CCC(Nc3ccc4c(c3)-c3ccccc3C4)CC2)OO1
|
[
"anti malarial"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a human metabolite that impacts schizophrenia, dermal fibroproliferative disorder, and mastocytosis.
|
Cn1cnc(CCN)c1
|
[
"human metabolite",
"Schizophrenia",
"Dermal fibroproliferative disorder",
"Mastocytosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is photosensitive.
|
CCC(C)Oc1ccc(C(C)c2ccc(OC(C)(CC)C(C)(CC)C(=O)c3ccc(Oc4ccc(C(=O)C(C)CC)cc4)cc3)c(C)c2)cc1C
|
[
"photosensitive"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a ns5a inhibitor and is anti viral.
|
C=C(NC=C(c1csc2c(-c3ccc(-c4cnc(C5C=CCN5C(=O)CNC(=O)OC)[nH]4)cc3)csc12)C(C)CC)C1CCCN1C(=O)C(NC(=O)OC)C(C)C
|
[
"ns5a inhibitor",
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis and a cholesterol translocation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts aging and diabetic heart disease.
|
CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C
|
[
"Apoptosis",
"Tangier disease",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC
|
[
"Aging",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Apoptosis",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is both a anti inflammatory agent and a chymase inhibitor.
|
Cc1cccc2c1c(Cc1c(-c3ccc4ccccc4c3C(=O)O)nc3ccccn13)cn2CCC1CCCN1C
|
[
"anti inflammatory agent",
"chymase inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is both a diabetes treatment and a aldose reductase inhibitor.
|
O=C(O)CC1Oc2ccc(Cl)cc2N(Cc2nc3c(Cl)cc(Cl)c(Cl)c3s2)C1=O
|
[
"diabetes treatment",
"aldose reductase inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a mtor inhibitor and is anti cancer.
|
Cc1ccc(S(=O)(=O)N2CCC(c3nc(C4Cc5ccccc5N4)c4c(N)nccn34)CC2)cc1
|
[
"anti cancer",
"mtor inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the cb1 antagonist class of molecules.
|
COCC1CN(c2ccc(C)cc2Cl)C(c2ccc(Cl)cc2)CN1C(=O)Cc1cccc(Cl)c1
|
[
"cb1 antagonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts luminous efficiency.
|
c1ccc(-c2ccc(N(c3ccc(-c4cccc5c4-c4ccccc4C54c5ccccc5Oc5c4ccc4ccccc54)cc3)c3cccc4c3sc3ccccc34)cc2)cc1
|
[
"luminous efficiency"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and aging. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease.
|
CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC
|
[
"Tangier disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease.
|
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC
|
[
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a platelet aggregation inhibitor and anti thrombotic, and it impacts cardiovascular disease treatment.
|
CCOC(=O)CCN1CCNC(=O)C1
|
[
"anti thrombotic",
"platelet aggregation inhibitor",
"cardiovascular disease treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome. The molecule is a stabilizing mitochondrial structure that impacts diabetic heart disease, tangier disease, aging, and non-alcoholic fatty liver disease.
|
CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C
|
[
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CCCCC/C=C\CC1OC1C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCCCCCCCCCC
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the potassium channel modulator class of molecules.
|
O=C(NC(=O)C1CCCCCC1)c1nccn1-c1cc(C(F)(F)F)ccc1F
|
[
"potassium channel modulator"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is both a cystic fibrosis treatment and a cftr modulator.
|
Cc1ccc(S(=O)(=O)Oc2n[nH]c(=O)c3c2cnn3C)cc1
|
[
"cystic fibrosis treatment",
"cftr modulator"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a hcv inhibitor and belongs to the anti viral class of molecules.
|
COC(=O)NC(C(=O)N1CCCC1c1nc2c(ccc3cc(-c4ccc(-c5cnc(C6C7CCC(C7)N6C(=O)C(NC(=O)OC)C(C)C)[nH]5)cc4)ccc32)[nH]1)C(C)C
|
[
"anti viral",
"hcv inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a energy source, it impacts aging, and is smooth. The molecule is a stabilizing cytochrome oxidase, apoptosis, cholesterol translocation that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a emulsifier, a surfactant, and a nutritional supplement, and it impacts barth syndrome. The molecule is a membrane stabilizer, proton trap for oxidative phosphorylation, energy storage, food additive that impacts diabetic heart disease.
|
CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
|
[
"Smooth",
"Aging",
"Stabilizing mitochondrial structure",
"Energy source",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Emulsifier",
"surfactant",
"Nutritional supplement",
"Membrane stabilizer",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Energy storage",
"food additive"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy source, energy storage, inflammatory, membrane stabilizer that impacts atherosclerosis and obesity. The molecule is a fat storage that impacts both cancer and pancreatitis. The molecule is a nutrient and thyroxine treatment, impacting both cardiovascular disease and metabolic syndrome.
|
CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC
|
[
"Atherosclerosis",
"Obesity",
"Energy source",
"Energy storage",
"inflammatory",
"Membrane stabilizer",
"Cancer",
"Fat storage",
"Pancreatitis",
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, membrane stabilizer, nutrient, apple, cut grass, and marigold. The molecule is a flavoring agent, energy source, energy storage, emulsifier, herbal, and fruity.
|
COc1cc(CCCO)ccc1OC(CO)COC1OCC(O)C(O)C1O
|
[
"surfactant",
"apple",
"cut grass",
"marigold",
"Membrane stabilizer",
"nutrient",
"herbal",
"Flavoring agent",
"Energy source",
"Energy storage",
"Emulsifier",
"fruity"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a organic electroluminescent device and belongs to the electroluminescent class of molecules.
|
c1ccc(-c2ccc(-c3ccc(-c4cccc(N(c5cccc(-c6ccccc6)c5)c5ccc6c(c5)oc5ccccc56)c4)cc3)cc2)cc1
|
[
"organic electroluminescent device",
"electroluminescent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule has Strong vinegar-like odor. Chloroacetic acid decomposes on heating producing toxic and corrosive hydrogen chloride, phosgene gases.
|
O=C(O)CCl
|
[
"Odor_evaluation",
"Decomposition_evaluation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a organic electroluminescent element and is both electroluminescent and belongs to the organic electroluminescent device and organic electroluminescent material classes of molecules.
|
c1ccc(-c2nc(-c3cccc(-c4cccc5c4oc4ccccc45)c3)cc(-c3ccccc3-n3c4ccccc4c4ccccc43)n2)cc1
|
[
"organic electroluminescent device",
"organic electroluminescent material",
"organic electroluminescent element",
"electroluminescent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts cystic fibrosis treatment.
|
CCc1nc(N)c2c(-c3cnco3)c[nH]c2n1
|
[
"cystic fibrosis treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule has Fishy. When heated to decomposition it emits toxic fumes such as nitrogen oxides.
|
CNCCO
|
[
"Odor_evaluation",
"Decomposition_evaluation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts aging, barth syndrome, and non-alcoholic fatty liver disease.
|
CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC
|
[
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, energy source, nutrient, energy storage, emulsifier, membrane stabilizer.
|
CCCCCCCC/C=C\CCCCC/C=C/C(=O)CC(O)COC(C)=O
|
[
"surfactant",
"Energy source",
"nutrient",
"Energy storage",
"Emulsifier",
"Membrane stabilizer"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a flavoring agent, powdery, fatty, and musk. The molecule is a nutrient, animal, sweet, and natural.
|
O=C(O)/C=C\c1cnc[nH]1
|
[
"powdery",
"Flavoring agent",
"fatty",
"musk",
"animal",
"nutrient",
"sweet",
"natural"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the anti convulsant class of molecules.
|
Cc1nc2c3c(Cl)cccc3n3cnc(-c4noc(C5CC5)n4)c3n2n1
|
[
"anti convulsant"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts diabetic heart disease, aging, tangier disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC
|
[
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Tangier disease",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CC(=O)CC[C@H]1C(C)=CCCC1(C)C
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy storage, surfactant, nutrient, aldehydic, fern, and green. The molecule is a membrane stabilizer, energy source, emulsifier, earthy, cumin, and cortex.
|
CC(O)C(O)C(O)CO
|
[
"Energy storage",
"aldehydic",
"surfactant",
"nutrient",
"fern",
"green",
"earthy",
"Membrane stabilizer",
"cumin",
"Energy source",
"Emulsifier",
"cortex"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a membrane stabilizer and energy storage, affecting cancer, and impacting pancreatitis, obesity, and thyroxine treatment. The molecule is a nutrient and energy source, and it impacts atherosclerosis. The molecule is a fat storage and a inflammatory, impacting both cardiovascular disease and metabolic syndrome.
|
CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C
|
[
"Pancreatitis",
"Membrane stabilizer",
"Obesity",
"Energy storage",
"Cancer",
"Thyroxine treatment",
"Atherosclerosis",
"nutrient",
"Energy source",
"Cardiovascular disease",
"Metabolic syndrome",
"Fat storage",
"inflammatory"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, tangier disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC
|
[
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease. The molecule is a stabilizing mitochondrial structure that impacts aging, barth syndrome, non-alcoholic fatty liver disease, and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCCCC
|
[
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.